BioCentury’s roundup of translational innovations also includes blood detection of pregnancy complications, BBB-crossing antibodies, and more

The company will also advance three heart disease platforms in parallel

BioMarin turns to external innovation to build its preclinical gene therapy pipeline

How China’s response to CRISPR fallout could elevate its global research reputation

How MyoKardia’s clinical cardiomyopathy data inspired its next candidates

Questions about CRISPR gene editing in human embryos highlight need for assays

Embryo study’s success is shifting the topic from ethics to efficacy